To the Editor Dr Huang and colleagues1 showed the benefits of using a drug with a better resistance profile (entecavir) in preventing hepatitis B virus (HBV) reactivation in patients with lymphoma receiving chemotherapy who were seropositive for the hepatitis B surface antigen. Only 6.6% (n = 4) of patients experienced HBV reactivation in the entecavir group.
Baang J. Treatment to Prevent Hepatitis B Virus Reactivation in Patients With Lymphoma Receiving Chemotherapy. JAMA. 2015;313(12):1269-1270. doi:10.1001/jama.2015.1438